

## FULL YEAR RESULTS AND BUSINESS UPDATE PRESENTATION

**BRISBANE, AUSTRALIA, 28 AUGUST 2025:** AnteoTech Ltd (ASX: ADO) (AnteoTech or the Company) provides the attached Full Year Results and Business Update presentation. The presentation accompanies the live webinar to be hosted by AnteoTech's CEO and Managing Director, Merrill Gray scheduled for 2pm AEST on Thursday, 28 August 2025.

To register and join the webinar please use the below link. A replay of the webcast will be made available as soon as possible following the conclusion of the event on the Investor Centre of the Company's website.

### Investor Call Details

Investors and analysts wishing to attend the investor webinar can register using the link below:

**Date:** Thursday, 28th August 2025

**Time:** 2pm AEST

**Webcast Link:** [https://us02web.zoom.us/webinar/register/WN\\_2a9FO9UfQLaxpneVqdmtnA](https://us02web.zoom.us/webinar/register/WN_2a9FO9UfQLaxpneVqdmtnA)

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

**Media and investor enquiries:** on +61 7 3219 0085 or [investors@anteotech.com](mailto:investors@anteotech.com)

**Company and Partnering enquiries:** Merrill Gray, CEO/MD, on + 61 7 3219 0085

For further information, please check our website [www.anteotech.com](http://www.anteotech.com)

### About AnteoTech - (ASX:ADO)

AnteoTech is a supplier of advanced material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemistry platform technology to develop and commercialise solutions for our global customer base. From our patented cross linker and binder product Anteo X™ to our next-generation high silicon anode formulations, Ultranode™, our Advanced Battery Technology business is applying its world-leading engineering expertise to address the growing demand for high performance, low cost, sustainable materials within the global battery market. Our Life Sciences business supplies advanced activation materials through our Anteobind™ suite of products to leading developers and manufacturers of vaccines and diagnostic tests. Our products deliver more sensitive and reproducible results and on incorporation in 'point of care' tests, enable faster, more reliable and accurate test results wherever they are needed.

### AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at [www.anteotech.com](http://www.anteotech.com) and subscribe to receive our email alert service.

### Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech’ business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

# Investor Update

**28/8/2025**

**Merrill Gray, MD/CEO**



# Disclaimer



## **IMPORTANT INFORMATION**

The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX:ADO) (AnteoTech). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by AnteoTech and should not be relied upon as an independent source of information. Please contact AnteoTech and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

## **FORWARD-LOOKING STATEMENTS**

The presentation may contain certain “forward-looking statements”. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “aim”, “estimate”, “target”, “anticipate”, “believe”, “continue”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding AnteoTech's intent, belief or current expectations with respect to AnteoTech's business and operations, market conditions, results of operations and financial condition, capital adequacy and risk management. These forward-looking statements should not be relied upon as a representation or warranty, express or implied, as to future matters. Prospective financial information has been based on current expectations about future events and is, however, subject to risks, uncertainties, contingencies and assumptions that could cause actual results to differ materially from the expectations described in such prospective information. AnteoTech disclaims any obligation to update any forward-looking statement to reflect events or circumstances after the date of the presentation, subject to the disclosure requirements applicable to the Group.

## **NOT AN OFFER OF SECURITIES**

This presentation should not be relied on as a recommendation or forecast by AnteoTech. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. The information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account your financial objectives, situation or needs. Investors should consult with their own legal, tax, business and/or financial advisors in connection with any investment decision.



# Agenda



- **Introduction to AnteoTech**
  - Our story
  - Our patented products and customer offering
  - Strategy and target markets
- **Life Sciences including growth pipeline and plans**
- **Advanced Battery Materials including growth pipeline and plans**
- **FY2025 Financial performance**
- **Moving Forward**



# **Introduction to AnteoTech**



# Who we are

- **AnteoTech Limited** is an Australian Stock Exchange listed (**ASX:ADO**) **chemical and materials company**, with **global sales** and an **expanding customer base**. The Company is at commercialisation and revenue growth stage of development.
- AnteoTech's expertise lies at its core in the application of **"Cross linking" binder chemicals (patent protected)**. Our technology is suitable for use in a range of industrial applications.
- This "Cross linker" **functions at a molecular level**. It is a strong double-sided "tape" or structural bond which secures to other molecules and surfaces and is uniquely, highly selective.
- ADO is **headquartered in Brisbane, Australia** and comprises of a team of 24 scientists, sales professionals and commercial analysts. We have **market leading know-how** and exciting potential for **growth across our existing businesses and beyond**.


# Our story




- Our **proprietary binding platform technology** has applications across multiple industries.
- Our current product portfolio comprises of **AnteoBind™, Anteo X™ and Ultranode™ technology**. Each
  - **Improves performance and lowers production costs across a range of applications.**
- The Company's focus is on **commercialising our products and growing sales revenue**.
- Over the past few months there have been foundational changes in relation to people, systems and ways of working to underpin accelerated commercialisation.
- A range of opportunities across global life sciences and battery markets are actively being pursued, including:-
  - **Growth of sales in India, South Korea and the USA**; growing in our already established life sciences markets and expanding into growing battery markets in consumer, drone, wearable and e-mobility applications.
  - **Reinvigorating previous and creating new relationships in Europe**; developing strategic partnerships with large chemical and pharma companies.
- AnteoTech has a pipeline of sales opportunities across both the Life Sciences and Battery businesses and has also commenced engagement with a number of potential strategic partners.
- **The Company is well positioned to achieve significant progress moving forward.**



# Our business



## Life Sciences



- Products, Services - Sales revenue.
- Expertise.
- Adjacent opportunities.

Patent protected (Family of 8)


## Advanced Battery Technologies



- Products, Technologies, Services – Early revenue.
- Expertise.
- Adjacent opportunities.

Patent protected (Family of 9)

## Potential other applications



- Superconductors
- Water treatment.
- Coatings.
- Air filtration.
- Niche fertilizers and/or pesticides.
- Textiles.


IP portfolio protection across broad strategy/capabilities

# What our patented products do

- Our products **strongly link/bind to functional groups of polymers and biomolecules, as well as surfaces** (act like double sided “tape”).
- Plus, they can bring special orientation properties to this bonding, that allows specificity/targeting of certain molecules.
- We know how to manipulate the bonds made (delay reaction/set conditions)

## Life Sciences

*Binds various molecules together and binds molecules to surfaces*




## Advanced Battery Technologies

*An additive that “cross links” high silicon in anodes*



*A high silicon anode formulation technology*



# What we offer customers

## In Life Sciences: AnteoBind™ and AnteoBind NXT™

- **Reduce customers costs** by:
  - **Reducing the antibody usage levels** in new test development
  - Reducing manufacturing costs by **improving workflow and assay reproducibility**
- Enabling accelerated development of highly sensitive and robust tests, **improving performance** in consumer and medical applications.

## In Advanced Battery Technologies:

### a) Anteo X™



- Improves high silicon anode performance and as a result **improves battery performance**.
- **Reduces costs** by using less additives e.g. carbon nanotubes or binders.

### b) UltranodeX™

- Basis/formulation that enables use of high silicon content anodes. Targeting a **+30% increase in energy density** on incorporation into commercial form factor cells and benefits such as:
  - In electric vehicles, **significant driving range extensions** for the same battery pack size.
  - In consumer applications, potentially **30% smaller batteries**.
  - **Faster charging and longer run times**.



# Our strategy and target markets

 Existing markets where opportunities will continue to be pursued
  New opportunities to be targeted and pursued

## Strategy

## Life Sciences

## Advanced Battery Technologies

### India



- Targeted, existing network facilitated **expansion of our commercialisation pipeline**. Plus, securing of strategic partnerships (through a profit repatriation model).

- Expansion through our **SII relationship and others**.
- Accelerated expansion working with Austrade and TIQ and more.

- E-Mobility, Wearables manufacturers and Suppliers targeted. Joint Venture/ Product Development focus.

### USA



- Expansion of our customer base. Attract a **Strategic partner**.

- POCT Diagnostics, Particle and Plate markets.

- Defence and Security.
- Carbon Nanotube joint product development.

### South Korea & Japan



- Expand our customer base for sales - short term. Attract **strategic partners**.

- Work with Distributors.
- Expand pipeline with Austrade & TIQ.

- Work with Distributor
- Expand pipeline working with Austrade & TIQ.

### Europe



- Expand existing customer base attract **strategic partners**.

- Re-engagement with known global Life Sciences companies is underway.

- WYON and others.

# Life Sciences

## Current products



Services and know how





# Life Sciences and the India market

- The **global Life Sciences market** was valued at ~ **US\$40 billion in 2024** and projected to grow to around ~**US\$120 billion (a factor of 3) by 2034**, at ~12% CAGR.
- **India** ranks amongst the **top global biotech** destinations.
- The **Indian government is heavily investing** in leadership in **bio innovation, biomanufacturing, and biotechnology** including through the “Health for All” initiative.
- In India there are:
  - 74+ Bio-incubators.
  - US\$17 billion of revenue is expected to be generated from vaccines in 2025.
  - 800+ Core Biotech Companies.
  - 6000+ Biotech Startups. With this to grow to 10,000+.
- AnteoTech’s products can **support accelerated, robust innovation**.

Source: <https://www.neovantage-parks.com/media/how-is-india-shaping-the-future-of-global-biotech>, December 2024



# What is it about India?


<b>Demand at scale</b>	1,450,935,791 people <sup>1</sup>
<b>Developing nation</b>	Two thirds rural population <sup>1</sup>
<b>Aging population</b>	Median Age 28.8 in 2025 expected to reach 38.3 in 2050 <sup>2</sup>
<b>Improved life expectancy</b>	Life expectancy of 67 in 2021 expected to reach 84 years in 2045 <sup>2</sup>
<b>Growing middle class</b>	Middle class 31% currently, expected to be 47% by 2030 <sup>3</sup>

Source: (1) India Demographics 2024 (Population, Age, Sex, Trends) – Worldometer; (2) Indian Healthcare Market projected to reach \$638 billion by 2025, report reveals - Healthcare News | The Financial Express; (3) Indian middle class will nearly double to 61% by 2046-47: PRICE Report | IBEF

# The 'Health for All' Indian Government Initiative

## 2/3 of India's Population is Rural<sup>1</sup>

Means Point of Care/Use Diagnostics are important to close to 1 billion people.




## Users Pay<sup>2</sup>

A rapidly growing market based on people's capacity to pay.

## Health expenditure per person

Among the BRICS and other newly industrialised nations, India spends the least on health per capita.



Source: (1) India Demographics 2024 (Population, Age, Sex, Trends) – Worldometer (2) Reshaping Inclusive Health Care in India



# Vaccine development & Point of Care lateral flow tests

Other opportunities exist to expand product use/applications

## Pharmaceuticals



- Targeted Drug Delivery e.g. in cancer treatment
- Bioseparation e.g. Protein, Antibody, Vaccine Purification

## Biotechnology



- Biosensor development
- Food processing

## Immunoassays



- Multiplex
- ELISA

## Recent Case Studies:

### Serum Institute of India

Multiplexed bead-based assay for the simultaneous quantification of human serum IgG antibodies to tetanus, diphtheria, pertussis toxin, filamentous hemagglutinin, and pertactin


Vishal Rathod<sup>1</sup>, Laxmikant Kadam<sup>1</sup>, Manish Gautam<sup>1</sup>, Prabhu Dasu Gumma<sup>1</sup>, Kevin Marke<sup>2</sup>, Cathy Asokanathan<sup>2</sup>, Alex Douglas-Bardsley<sup>2</sup>, Laura Hassell<sup>2</sup>, Sachin Bhandare<sup>1</sup>, Sumit Gupta<sup>1</sup>, Sameer Parekh<sup>1</sup>, Pramod Pujari<sup>1</sup>, Harish Rao<sup>1</sup>, Hitt Sharma<sup>1</sup>, Umesh Shaligram<sup>1</sup> and Sunil Gairola<sup>1\*</sup>

<sup>1</sup>Clinical Bioregulatory Laboratory, Serum Institute of India Pvt. Ltd., Pune, Maharashtra, India; <sup>2</sup>Science, Research and Innovation, Medicines and Healthcare Products Regulatory Agency, South Mimms, United Kingdom

### Quantitative Point of Care Tests for Timely Diagnosis of Early-Onset Preeclampsia with High Sensitivity and Specificity

Sahar Masoumeh Ghorbanpour<sup>\*</sup>, Shihui Wen<sup>\*</sup>, Tu'uhevaha J Kaitu'u-Lino, Natalie J. Hannan, Dayong Jin, and Lana McClements<sup>\*</sup>

# How AnteoBind™ works





# Growth Plans



— MARKETS —

Continued growth in **India**.

Growth in other markets such as **South Korea** (e.g. KOMA), **USA** and **Japan**.

Strategic Partnership engagement in **Europe** with large chemical companies.

Potentially entry into **China**, with the right partner.

— APPLICATIONS —

Growth in **vaccine development use** and **lateral flow diagnostic test use**.


Expansion **into new applications** e.g. Pharmaceuticals, Biotechnology and Immunoassays,

Further expansion into **Animal use in point of care tests/lateral flow diagnostics**.

Expansion into **Biosecurity**.

# Opportunity pipeline

● AnteoBind    ● AnteoBind NXT    ~ 80/20 split



# Advanced Battery Technologies

## Current products



ANTEO X



ULTRANODE

Services and know how

# The Lithium ion Battery (LiB) supply chain is complex

UPSTREAM

MIDSTREAM

DOWNSTREAM

MINING/CHEMICALS

LiB  
MATERIALS

LiB  
COMPONENT  
PRODUCTION

LiB ASSEMBLY

END LiB USE

## Newly mined raw materials

- Hard rock & Brines:- Li,
- NMC/NCA LiBs – Ni (Laterite & Sulphides) Mn, Co, Al
- LFP LiBs – Fe
- LCO & LMO LiBs
- Graphite (C), Silica (SiO<sub>2</sub>)
- Other e.g. Exotics. Nb, Ti



## Chemicals

- Chemical plants – main product and by-product or from blended sources (multi-source)
- Silicon
- Other



## LiB recycling materials

LiSO<sub>4</sub>, Li<sub>2</sub>CO<sub>3</sub>  
LiOH, LiF,  
NiSO<sub>4</sub> etc



## Processing/refining

Graphite  
Silicon

## pCAM chemicals

e.g. Li<sub>2</sub>CO<sub>3</sub>,  
LiOH, CoSO<sub>4</sub>,  
MnSO<sub>4</sub>, NiSO<sub>4</sub>



## Anode

Graphite,  
Silicon & Coatings

**ULTRANODE**



## Separator

## Cathode

- NMC, LFP, Other



## Electrolyte\*



Binders, additives,  
nanotubes **ANTEOX**

Other e.g. Copper,  
Aluminum, Plastic,  
Paper, Water



## LiB manufacture – multi format

- Internal frame/ infrastructure
- Anode, Separator, Electrolyte, Cathode, Binders, Additives, Nanotubes etc
- External Packaging



## End Use

e.g. EV, BESS, E-Mobility,  
Computing and IT &  
Telecommunications



Plus, repurposing  
and recycling!



©Wolf Consulting. Adapted: Slide 11, The current battery value chain complications and what companies can do to prepare for the future? March 2022, Ken Hoffman, McKinsey & Co. Original

Source: McKinsey; Yano Research; Expert interviews; Papers. Notes: CAM (Cathode Active Material), PCAM (Precursor Cathode Active Material),


((\*) LiB electrolyte composition is mainly composed of three parts: (1) solvent: cyclic carbonate (PC, EC), chain carbonate (DEC, DMC, EMC), carboxylic acid esters (MF, MA, EA, MA, MP etc.) (used to dissolve lithium salt), (2) lithium salt: LiPF<sub>6</sub>, LiClO<sub>4</sub>, LiBF<sub>4</sub>, LiAsF<sub>6</sub>, etc. (3) additives: film forming additives, conductive additives, flame retardant additives, overcharge protection additives, additives to control the content of H<sub>2</sub>O and HF in the electrolyte

# LiB market is growing rapidly

The LiB market had an estimated value of ~US\$160 billion in 2024...


... the LiB market is forecast to grow at a **compound annual growth rate (CAGR)** of ~**20%** between out to 2030.

*Li-ion cells sold worldwide, 2015-2024, US\$Mn*



Source: Avicenne Energy 2025

*Market value at Pack level<sup>1</sup>, 2010-2030, in US\$Bn*



Source: Avicenne Energy 2025

**AnteoTech's focus is high silicon anodes within the LiB market**




# The future is in Silicon anodes



## Silicon anode production capacity forecast to triple this year

Capacity is expected to more than double next year, too




# x10

*Growth over the next ten years (off the 2024 base) is forecast*

Silicon anodes prepare for mainstream deployment with production capacity set to triple in 2024 and grow by a factor of ten out to 2035.  
**Benchmark Minerals Communication 18<sup>th</sup> July 2024**

## Why high silicon anodes?

- Silicon (Si) has the potential to deliver **higher energy density and smaller anodes** in LiBs than graphite.
- Si possesses very **high gravimetric capacity** (at 4200 mA h/g, lithiated to  $\text{Li}_{4.4}\text{Si}$ ), relative to Graphite (at a 372 mAh/g) - **more than 10 times**.
- Silicon is **sourced from  $\text{SiO}_2$**  the **second most abundant mineral** in the earth's crust.
  - Metallurgical Silicon is produced using an **Electric Arc Furnace – limited processing compared to highly engineered alternatives – Ultranode™ uses this lower cost material**
- Challenges exists around widespread adoption of due to Silicon's **expansion properties (+300%) in battery operation** (lithiation and delithiation).




# Anteo X™ performance improvements achieved



Example: a High Silicon anode formulation, at 20% Si/C including Anteo X™

Using half the amount of CNT a 38% cycle life improvement was achieved

With the addition of Anteo X™ and binder optimisation.



Source: AnteoTech's 26 June 2025 ASX Announcement. For the 15th International Advanced Automotive Battery Conference (AABC) Europe presentation titled "Maximising high silicon anode performance" (page 18),



# Anteo X™ production facility's expansion capacity




Located at AnteoTech's headquarters in Brisbane  
Our processes are ISO 9001 certified.

**20,000 liters /  
year**

Current production capacity

**80,000 liters /  
year**

Capacity to expand



# Ultranode™ is highly customisable



## Applications

### Ultranode™ 95

- Targets **high energy, low cycle-life** applications e.g. **Unmanned Aerial Systems (UAS)** and **drones**.

### Ultranode™ 70

- Balances **energy density with attractive cycle-life**
- Targets **medium energy and medium cycle-life** applications e.g. **Computer, Communications** (mobile phone) and **Consumer Electronics** (incl wearables)
- **E-Mobility** such as two- and three-wheeler applications, customisable across a range capacities

### Ultranode™ X

- **890 cycles @80% capacity has been achieved for a 70% silicon anode and 1,070 cycles @70% capacity**
- Maximises cycle-life for **high energy, high cycle-life** applications such as that required for **EVs**. It can deliver:
  - Longer cycle-life.
  - Specification, customisation capacity driven by customer/partner requirements.

## Composition

- Higher capacity anode coatings of **1,800 - 2,400mAh/g @C/20**.
- Cycle-life up to **380 cycles @ 80% capacity retention**.

- Medium capacity anode coatings of **600 - 1,200 mAh/g**.
- Intermediate cycle-life of up to **670 cycles @ 80% capacity retention**.

- Coating capacities of between **900 - 1,100mAh/g @C/20**.
- High **first cycle efficiencies of >90%**.

# Growth Plans

## MARKETS

Growth in **USA**, off the BDS JDA with a focus on Defense and Security.

Growth in **South Korea** working with local Distributor.

Growth in **India** working with Austrade and TIQ in terms of pipeline development.

Potentially **China**, with the right partner.

## APPLICATIONS


Expansion of Anteo X™ applications including through further **development of joint or combined products similar to BDS** e.g. binders and separator – Anteo S.

Ultranode™ uptake – into a range of applications. **Wyon is the first, in wearables.**

**Strategic Partnership in market leading battery design, development and sales** – e.g. UltranodeX™ further development leveraging in the ARENA grant (A\$4 million)



# Opportunity pipeline



## Opportunities by geography

- 29% Europe
- 28% USA/Canada
- 11% India
- 11% China
- 7% Japan
- 5% South Korea


# Financial Performance



# Our sales revenue continues to grow



Total sales  
revenue  
AUD\$




Source: ADO Annual Reports and Internal data; 250630 Expense Account Mapping\_HM.xlsx; <https://www.listcorp.com/asx/ado/anteotech/news/2023-annual-report-2917473.html>  
Note: Periods stated represent financials years e.g. 2023 is 2022/2023 Financial Year.

# Cash management focus

Real cost reduction of ~ 10% on 2024 was achieved. The R&D tax rebate (A\$2.6 m) was accelerated.

## Total cash costs (pre-R&D rebate)



Source: ADO Annual Reports and Internal data; 250630 Expense Account Mapping\_HM.xlsx; <https://www.listcorp.com/asx/ado/anteotech/news/2023-annual-report-2917473.html>



# Operational highlights for FY2025



## Strategic Partnership with Black Diamond Structures (USA)

Entered into a **binding Term Sheet for a Joint Development Agreement** to produce and commercialise an advanced battery product **combining Anteo X™ cross linker with BDS's proprietary carbon nanotube technology**, to deliver step-change performance improvements in high-silicon LiBs for customers.

## Collaboration with Wyon (Switzerland)

Reached **agreement with Wyon**, a leading miniature battery manufacturer, to **evaluate AnteoTech's Ultranode™ high-silicon anode technology for potential integration** into commercial-scale production.

## Major Technical Milestone for Ultranode™ X

Achieved **890 cycles at 80% capacity retention and 1,070 cycles at 70% capacity retention for the Company's 70% silicon anode**, market-leading capabilities...paving the way for further advancements toward 1,000 cycles at 80% retention.

## 5-Year Supply Agreement with Serum Institute

Under the **purchase agreement for AnteoBind™** valued at a minimum of US\$1.8 million, **FY2025 orders of approximately US\$580,000** were secured (a level above forecast).

## Commercial Evaluation with Vidcare Innovations

Entered into a program **to support Vidcare's first in-home diagnostic test for hyperthyroidism** using AnteoBind™ NXT, positioning AnteoTech for broader adoption across future point-of-care applications.

EXPANSION INTO KEY ASIAN BATTERY  
MARKET THROUGH APPOINTMENT  
OF SOUTH KOREAN DISTRIBUTOR  
12 August 2025

**Kangshin Industrial Co Ltd**

강  
신 剛信  
*Kangshin*

MOBIUS LAUNCH  
La Trobe University  
15 August 2025



Home About us ▾ Research Partnerships Events News Contact Portal

## About us

The ARC Research Hub for Molecular Biosensors at Point-of-Use (MOBIUS) is a multi-million-dollar research scheme funded by the Australian Research Council (ARC), and led by La Trobe University.



Sources: <https://www.arc.gov.au/news-publications/media/arc-corporate-article/advancing-australian-biotechnology-sector> and <https://mobius.org.au/about>

# Strategic partnerships discussions

- Discussions are underway with **a range of businesses globally.**
- **Target of Q4 FY26 to provide** public transparency around commercial engagement structure.

**3**

Chemical and  
Materials Supply/  
Distribution  
Companies

**3**

Battery  
Manufacturers

**1**

Diversified Large  
Multi-Nationals

**2**

Big Pharma

- The Company's focus is on **commercialising our products and growing sales revenue.**
- Over the past few months there have been foundational changes in relation to people, systems and ways of working that will underpin accelerated commercialisation.
- A range of opportunities across global life sciences and battery markets are actively being pursued, including:-
  - **Growing sales in India, South Korea and the USA;** growing in already established life sciences markets and expanding into established and growing consumer, drone, wearable and e-mobility battery markets.
  - **Reinvigorating previous and creating new relationships in Europe;** developing strategic partnerships with large chemical and pharma companies.
  - Entry into China potentially, with the right partner. On the right terms and conditions.
- AnteoTech has a pipeline of sales opportunities across both businesses and has commenced engagement with potential strategic partners.
- **The Company is well positioned to achieve significant progress moving forward.**



# Questions?



# Further materials available

## Immediately available on AnteoTech's website:

- Product brochures – Anteo X™, Ultranode™, AnteoBind™ including NXT and Corporate flyer
- AnteoBind NXT™ “White Paper” – 4 page summary (general) and ~20 page technical expert/customer version

## In progress/available shortly:

- Anteo X™ and Ultranode™ /High Silicon Anode “White Paper”.

## Contact:

**Merrill Gray**

[merrill.gray@anteotech.com](mailto:merrill.gray@anteotech.com)

+61 (07) 3219 0085

[www.anteotech.com](http://www.anteotech.com)